Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

Open access
van Tilburg, Cornelis M., Pfaff, Elke, Pajtler, Kristian W., Langenberg, Karin P.S., Fiesel, Petra, Jones, Barbara C., Balasubramanian, Gnana Prakash, Stark, Sebastian, Johann, Pascal D., Blattner-Johnson, Mirjam, Schramm, Kathrin, Dikow, Nicola, Hirsch, Steffen, Sutter, Christian, Grund, Kerstin, von Stackelberg, Arend, Kulozik, Andreas E., Lissat, Andrej, Borkhardt, Arndt, Meisel, Roland, Reinhardt, Dirk, Klusmann, Jan-Henning, Fleischhack, Gudrun, Tippelt, Stephan, von Schweinitz, Dietrich, Schmid, Irene, Kramm, Christof M., von Bueren, André O., Calaminus, Gabriele, Vorwerk, Peter, Graf, Norbert, Westermann, Frank, Fischer, Matthias, Eggert, Angelika, Burkhardt, Birgit, Wößmann, Wilhelm, Nathrath, Michaela, Hecker-Nolting, Stefanie, Frühwald, Michael C., Schneider, Dominik T., Brecht, Ines B., Ketteler, Petra, Fulda, Simone, Koscielniak, Ewa, Meister, Michael T., Scheer, Monika, Hettmer, Simone, Schwab, Matthias, Tremmel, Roman, Øra, Ingrid, Hutter, Caroline, Gerber, Nicolas U., Lohi, Olli, Kazanowska, Bernarda, Kattamis, Antonis, Filippidou, Maria, Goemans, Bianca, Zwaan, C. Michel, Milde, Till, Jäger, Natalie, Wolf, Stephan, Reuss, David, Sahm, Felix, von Deimling, Andreas, Dirksen, Uta, Freitag, Angelika, Witt, Ruth, Lichter, Peter, Kopp-Schneider, Annette, Jones, David T.W., Molenaar, Jan J., Capper, David, Pfister, Stefan M., Witt, Olaf·2021·Cancer Discovery

Abstract

INFORM is a prospective, multinational registry gathering clinical and molecular data of relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long-term follow-up of 519 patients in whom molecular alterations were evaluated according to a predefined seven-scale target prioritization algorithm. Mean turnaround time from sample receipt to report was 25.4 days. The highest target priority level was observed in 42 patients (8.1%). Of these, 20 patients received matched targeted treatment with a median progression-free survival of 204 days [95% confidence interval (CI), 99–not applicable], compared with 117 days (95% CI, 106–143; P = 0.011) in all other patients. The respective molecular targets were shown to be predictive for matched treatment response and not prognostic surrogates for improved outcome. Hereditary cancer predisposition syndromes were identified in 7.5% of patients, half of which were newly identified through the study. Integrated molecular analyses resulted in a change or refinement of diagnoses in 8.2% of cases. Significance: The pediatric precision oncology INFORM registry prospectively tested a target prioritization algorithm in a real-world, multinational setting and identified subgroups of patients benefiting from matched targeted treatment with improved progression-free survival, refinement of diagnosis, and identification of hereditary cancer predisposition syndromes. See related commentary by Eggermont et al., p. 2677 . This article is highlighted in the In This Issue feature, p. 2659

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0094

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Metadata

Authors
van Tilburg, C. M., Pfaff, E., Pajtler, K. W., Langenberg, K. P. S., Fiesel, P., Jones, B. C., Balasubramanian, G. P., Stark, S., Johann, P. D., Blattner-Johnson, M., Schramm, K., Dikow, N., Hirsch, S., Sutter, C., Grund, K., von Stackelberg, A., Kulozik, A. E., Lissat, A., Borkhardt, A., Meisel, R., Reinhardt, D., Klusmann, J.-H., Fleischhack, G., Tippelt, S., von Schweinitz, D., Schmid, I., Kramm, C. M., von Bueren, A. O., Calaminus, G., Vorwerk, P., Graf, N., Westermann, F., Fischer, M., Eggert, A., Burkhardt, B., Wößmann, W., Nathrath, M., Hecker-Nolting, S., Frühwald, M. C., Schneider, D. T., Brecht, I. B., Ketteler, P., Fulda, S., Koscielniak, E., Meister, M. T., Scheer, M., Hettmer, S., Schwab, M., Tremmel, R., Øra, I., Hutter, C., Gerber, N. U., Lohi, O., Kazanowska, B., Kattamis, A., Filippidou, M., Goemans, B., Zwaan, C. M., Milde, T., Jäger, N., Wolf, S., Reuss, D., Sahm, F., von Deimling, A., Dirksen, U., Freitag, A., Witt, R., Lichter, P., Kopp-Schneider, A., Jones, D. T. W., Molenaar, J. J., Capper, D., Pfister, S. M., & Witt, O.
Venue
Cancer Discovery
Published
2021-08-09
Volume
11
Issue
11
Pages
2764-2779
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3190606189
Cited by
262
References
30
FWCI
14.19
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-0094
The paper
van Tilburg, C. M., Pfaff, E., Pajtler, K. W., Langenberg, K. P. S., Fiesel, P., Jones, B. C., Balasubramanian, G. P., Stark, S., Johann, P. D., Blattner-Johnson, M., Schramm, K., Dikow, N., Hirsch, S., Sutter, C., Grund, K., von Stackelberg, A., Kulozik, A. E., Lissat, A., Borkhardt, A., . . . Witt, O. (2021). The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-0094

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.